Advances in biologic therapy for the treatment of moderate to severe psoriasis: a systematic review
DOI:
https://doi.org/10.56183/iberojhr.v4i1.630Palavras-chave:
psoriasis, biologic therapy, immunotherapy, monoclonal antibodies, cytokine inhibitors, severe psoriasis.Resumo
We summarize that biologic therapies for moderate to severe psoriasis development has advanced enough as these therapies encompass biologic factors such as TNF-α inhibitors, IL-12/IL-23 inhibitors, and IL-17/IL-23 pathway inhibitors for psoriasis. First-generation biologics like etanercept, infliximab, and adalimumab offer substantial clinical improvements but carry risks of infections and malignancies. Second-generation agents, such as ustekinumab, provide targeted efficacy with fewer adverse effects. Third-generation biologics, including secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab, present highly specific mechanisms, achieving remarkable efficacy with manageable safety profiles. Despite challenges such as cost and long-term monitoring, these biologics represent a paradigm shift in psoriasis management, enhancing patient outcomes and quality of life.
Referências
Brownstone, N., MD. (2024, January 19). Psoriasis therapies in 2024 and beyond. Dermatology Times. https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond
Campa, M., Mansouri, B., Warren, R., & Menter, A. (2015). A review of biologic therapies targeting IL-23 and IL-17 for use in Moderate-to-Severe Plaque Psoriasis. Dermatology and Therapy, 6(1), 1–12. https://doi.org/10.1007/s13555-015-0092-3
Campa, M., Ryan, C., & Menter, A. (2015). An overview of developing TNF-α targeted therapy for the treatment of psoriasis. Expert Opinion on Investigational Drugs, 24(10), 1343–1354. https://doi.org/10.1517/13543784.2015.1076793
Deng YX, Chang C, Lu QJ. The Inflammatory Response in Psoriasis: A Comprehensive Review. Clin Rev Allergy Immunol (2016) 50(3):377–89. doi: 10.1007/s12016-016-8535-x
Eshwar, V., Kamath, A., Shastry, R., Shenoy, A. K., & Kamath, P. (2022). A review of the safety of Interleukin-17A inhibitor Secukinumab. Pharmaceuticals, 15(11), 1365. https://doi.org/10.3390/ph15111365
Fargnoli, M. C., Bardazzi, F., Bianchi, L., Dapavo, P., Fabbrocini, G., Gisondi, P., Micali, G., Offidani, A. M., Pellacani, G., Skroza, N., Angileri, R. G., Burlando, M., Campanati, A., Carrera, C. G., Chiricozzi, A., Conti, A., De Simone, C., Di Lernia, V., Errichetti, E., . . . Pinton, P. C. (2023). Brodalumab for the treatment of Moderate-to-Severe psoriasis: An Expert Delphi Consensus Statement. Journal of Clinical Medicine, 12(10), 3545. https://doi.org/10.3390/jcm12103545
Ghazawi, F. M., Mahmood, F., Kircik, L., Poulin, Y., Bourcier, M., Vender, R., Wiseman, M. C., Lynde, C., & Litvinov, I. V. (2021). A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.702776
Ghosh, S., Gensler, L. S., Yang, Z., Gasink, C., Chakravarty, S. D., Farahi, K., Ramachandran, P., Ott, E., & Strober, B. E. (2019). Ustekinumab Safety in Psoriasis, psoriatic arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III clinical Development programs. Drug Safety, 42(6), 751–768. https://doi.org/10.1007/s40264-019-00797-3
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023). Signaling pathways and targeted therapies for psoriasis. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01655-6
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018). Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. ˜the œJournal of Immunology/˜the œJournal of Immunology, 201(6), 1605–1613. https://doi.org/10.4049/jimmunol.1800013
Henrickson, S. E., Ruffner, M. A., & Kwan, M. (2016). Unintended immunological consequences of biologic therapy. Current Allergy and Asthma Reports, 16(6). https://doi.org/10.1007/s11882-016-0624-7
Hu, P., Wang, M., Gao, H., Zheng, A., Li, J., Mu, D., & Tong, J. (2021). The role of helper T cells in psoriasis. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.788940
Jang, D., Lee, A., Shin, H., Song, H., Park, J., Kang, T., Lee, S., & Yang, S. (2021). The role of tumor necrosis factor alpha (TNF-Α) in autoimmune disease and current TNF-Α inhibitors in therapeutics. International Journal of Molecular Sciences, 22(5), 2719. https://doi.org/10.3390/ijms22052719
Korta, A., Kula, J., & Gomułka, K. (2023). The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease. International Journal of Molecular Sciences, 24(12), 10172. https://doi.org/10.3390/ijms241210172
Koutruba, N., Emer, J., & Lebwohl, M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management, 123. https://doi.org/10.2147/tcrm.s5599
Kurtovic, N., & Halilovic, E. (2022). Serum Levels of Tumor Necrosis Factor - alpha in Patients With Psoriasis. Materia Socio-medica/Materia Socio Medica, 34(1), 40. https://doi.org/10.5455/msm.2022.33.40-43
Lee, H., & Kim, M. (2023). Challenges and future trends in the treatment of psoriasis. International Journal of Molecular Sciences, 24(17), 13313. https://doi.org/10.3390/ijms241713313
Lonnberg, N., Skov, L., & Zachariae, C. (2014). Targeting of interleukin-17 in the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology, 251. https://doi.org/10.2147/ccid.s67534
Ortiz-Lopez, L. I., Choudhary, V., & Bollag, W. B. (2022). Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders. Psoriasis, Volume 12, 73–87. https://doi.org/10.2147/ptt.s327310
Pirzada et al. (2018, September 24). A Review of Biologic Treatments for Psoriasis with Emphasis on Infliximab. Skin Therapy Letter. https://www.skintherapyletter.com/psoriasis/biologic-treatments-infliximab
Raharja, A., Mahil, S. K., & Barker, J. N. (2021). Psoriasis: a brief overview. Clinical Medicine, 21(3), 170–173. https://doi.org/10.7861/clinmed.2021-0257
Raychaudhuri, S., & Raychaudhuri, S. (2024). Biologics : Target - specific treatment of systemic and cutaneous autoimmune diseases. Indian Journal of Dermatology/Indian Journal of Dermatology, 54(2), 100. https://doi.org/10.4103/0019-5154.53175
Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475. https://doi.org/10.3390/ijms20061475
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021). Role of the IL-23/IL-17 pathway in Rheumatic Diseases: An Overview. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.637829
Torres, T., Chiricozzi, A., Puig, L., Lé, A. M., Marzano, A. V., Dapavo, P., Dauden, E., Carrascosa, J., Lazaridou, E., Duarte, G., Carvalho, A. V. E., Romiti, R., Rompoti, N., Teixeira, L., Abreu, M., Ippoliti, E., Maronese, C. A., Llamas-Velasco, M., Vilarrasa, E., . . . Gisondi, P. (2024). Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. American Journal of Clinical Dermatology, 25(2), 333–342. https://doi.org/10.1007/s40257-024-00845-4
Vidal, S., Puig, L., Carrascosa-Carrillo, J., González-Cantero, Á., Ruiz-Carrascosa, J., & Velasco-Pastor, A. (2021). From messengers to receptors in Psoriasis: The role of IL-17RA in Disease and treatment. International Journal of Molecular Sciences, 22(13), 6740. https://doi.org/10.3390/ijms22136740
Wang, Y., Zhang, P., Lv, Y., Deng, Y., Yao, M., Wang, L., & Pan, G. (2023). Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A literature review. Clinical, Cosmetic and Investigational Dermatology, Volume 16, 3487–3495. https://doi.org/10.2147/ccid.s439110
Yang, K., Oak, A. S. W., & Elewski, B. E. (2020). Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A Comprehensive review. American Journal of Clinical Dermatology, 22(2), 173–192. https://doi.org/10.1007/s40257-020-00578-0
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Josselyn Nicole Villarreal Enríquez, Mateo Daniel Fabara Vera, Vanessa Carolina Batallas Salazar, Gina Pierina Macías Pita, Adriana Pauleth Jaramillo Andrade, Yuliana Lisbeth Yuliana Lisbeth Merino Jiménez, María Joaquina Vargas Ladinez, Diana Elizabeth Singaña Paredez
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
